Recent studies by Long et al. [44] have shown that NOTCH4 mutations have better clinical benefits in patients with gastric cancer, and NOTCH4 mutations are significantly associated with enhanced immunogenicity, including TMB, co-stimulatory molecule expression and activation of antigen processing mechanisms. This evidence concerns the gene NOTCH4 and gastric cancer.